

Date: February 12, 1998.

Time: 8:00 a.m.

Place: Radisson Barcelo Hotel,
Washington, DC.

Contact Person: Dr. Leonard Jakubczak,
Scientific Review Administrator, 6701
Rockledge Drive, Room 5172, Bethesda,
Maryland 20892, (301) 435-1247.

This notice is being published less than 15
days prior to the above meetings due to the
urgent need to meet timing limitations
imposed by the grant review and funding
cycle.

Name of SEP: Biological and Physiological
Sciences.

Date: March 12-13, 1998.

Time: 8:30 a.m.

Place: Holiday Inn-Georgetown,
Washington, DC.

Contact Person: Dr. Betty Hayden,
Scientific Review Administrator, 6701
Rockledge Drive, Room 4206, Bethesda,
Maryland 20892, (301) 435-1223.

Name of SEP: Multidisciplinary Sciences.

Date: March 15-17, 1998.

Time: 7:00 a.m.

Place: Regal University Hotel, Durham, NC.
Contact Person: Dr. Lee Rosen, Scientific
Review Administrator, 6701 Rockledge Drive,
Room 5116, Bethesda, Maryland 20892, (301)
435-1171.

Name of SEP: Biological and Physiological
Sciences.

Date: March 16, 1998.

Time: 2:00 p.m.

Place: NIH, Rockledge 2, Room 6168,
Telephone Conference.

Contact Person: Dr. Syed Amir, Scientific
Review Administrator, 6701 Rockledge Drive,
Room 6168, Bethesda, Maryland 20892, (301)
435-1043.

Name of SEP: Chemistry and Related
Sciences.

Date: March 25-27, 1998.

Time: 8:00 p.m.

Place: Quality Suites, Rockville, MD.

Contact Person: Dr. Jean D. Sipe, Scientific
Review Administrator, 6701 Rockledge Drive,
Room 5152, Bethesda, Maryland 20892, (301)
435-1743.

Purpose/Agenda: To review Small
Business Innovation Research.

Name of SEP: Multidisciplinary Sciences.

Date: March 9-10, 1998.

Time: 8:30 a.m.

Place: Holiday Inn-Georgetown,
Washington, DC.

Contact Person: Dr. Bill Bunnag, Scientific
Review Administrator, 6701 Rockledge Drive,
Room 5212, Bethesda, Maryland 20892, (301)
435-1177.

Name of SEP: Chemistry and Related
Sciences.

Date: March 17-18, 1998.

Time: 8:00 a.m.

Place: Holiday Inn-Georgetown,
Washington, DC.

Contact Person: Dr. Jean D. Sipe, Scientific
Review Administrator, 6701 Rockledge Drive,
Room 5152, Bethesda, Maryland 20892, (301)
435-1743.

The meetings will be closed in accordance
with the provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5, U.S.C.
Applications and/or proposals and the

discussions could reveal confidential trade
secrets or commercial property such as
patentable material and personal information
concerning individuals associated with the
applications and/or proposals, the disclosure
of which would constitute a clearly
unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance
Program Nos. 93.306, 93.333, 93.337, 93.393-
93.396, 93.837-93-844, 93.846-93.878,
93.892, 93.893, National Institutes of Health,
HHS)

Dated: January 27, 1998.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 98-2559 Filed 2-2-98; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of Coexclusive License: Vaccines for Dengue and Other Flaviviruses

AGENCY: National Institutes of Health,
Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice in accordance
with 15 U.S.C. 209(c)(1) and 37 CFR
404.7(a)(1)(i) that the National Institutes
of Health (NIH), Department of Health
and Human Services, is contemplating
the grant of a limited field of use
coexclusive world-wide license to
practice the invention embodied in U.S.
Patent No. 5,494,671, issued February
27, 1996 (U.S. Patent Application Serial
No. 07/747,785, filed August 20, 1991),
entitled "C-Terminally Truncated
Dengue and Japanese Encephalitis Virus
Envelope Proteins" to SmithKline
Beecham Biological of Rixensart,
Belgium. Publication of this notice
should be considered a modification of
an earlier notice (62 FR 5836, Feb. 7,
1997). The patent rights in this
invention have been assigned to the
United States of America.

DATES: Only written comments and/or
applications for a license which are
received by NIH on or before April 6,
1998.

ADDRESSES: Requests for a copy of this
issued patent, inquiries, comments, and
other materials relating to the
contemplated license should be directed
to: Carol A. Salata, Technology
Licensing Specialist, Office of
Technology Transfer, National Institutes
of Health, 6011 Executive Boulevard,
Suite 325, Rockville, MD 20852-3804;
Telephone: (301) 496-7735 ext 232;
Facsimile: (301) 402-0220; E-mail:
salatac@OD.NIH.GOV.

SUPPLEMENTARY INFORMATION: The patent
describes the use of C-terminally
truncated flavivirus envelope proteins
in vaccines against flavivirus infections.
The inventions also relates to
recombinant viruses which encode the
truncated protein and to host cells
infected therewith.

The prospective coexclusive license
will be royalty-bearing and will comply
with the terms and conditions of 35
U.S.C. 209 and 37 CFR 404.7. It is
anticipated that this license may be
limited to the field of subunit vaccines
against Dengue and Japanese
Encephalitis produced in prokaryotic or
eukaryotic cells. This license will not
include live virus, killed virus or DNA-
based vaccines or the use of vaccinia
virus as a vector, or immunogen.

This prospective coexclusive license
may be granted unless within 60 days
from the date of this published notice,
NIH receives written evidence and
argument that establishes that the grant
of the license would not be consistent
with the requirements of 35 U.S.C. 209
and 37 CFR 404.7.

Applications for a license filed in
response to this notice will be treated as
objections to the grant of the
contemplated license. Comments and
objections submitted in response to this
notice will not be made available for
public inspection, and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.

Dated: January 23, 1998.

Barbara M. McGarey,

*Deputy Director, Office of Technology
Transfer.*

[FR Doc. 98-2562 Filed 2-2-98; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Public Health Service

National Toxicology Program; Call for Public Comments; Substances, Mixtures and Exposure Circumstances Proposed for Listing in or Delisting (Removing) From the Report on Carcinogens, Ninth Edition

Background

The National Toxicology Program
(NTP) announces its intent to review
additional substances, mixtures and
exposure circumstances for possible
listing in or delisting (removing) from
the Report on Carcinogens, Ninth
Edition. This Report (previously known
as the Annual Report on Carcinogens) is
a Congressionally-mandated listing of
known human carcinogens and